Shoaib Faruqi
Effect of ivacaftor on objective and subjective measures of cough in patients with cystic fibrosis
Faruqi, Shoaib; Shiferaw, Dejene; Morice, Alyn H.
Authors
Dejene Shiferaw
Professor Alyn Morice A.H.Morice@hull.ac.uk
Foundation Chair and Professor of Respiratory Medicine
Abstract
© Faruqi et al. Background and Objectives: Cough is a major symptom in cystic fibrosis. Ivacaftor is a novel drug which targets the G551D mutation and has been demonstrated to improve lung function and weight in the long term. It also improves symptoms of extra-oesophageal reflux. We wanted to evaluate the effect of ivacaftor on cough in cystic fibrosis. Methods: In two patients with cystic fibrosis the Hull Airway Reflux Questionnaire (HARQ) was completed and objective cough counts were measured prior to and within 4 weeks after initiation of treatment with ivacaftor. Spirometry was also undertaken and weight checked at these time frames. Results: In the first patient the HARQ score decreased from 29 to 11 and objective cough counts from 29 to 9 cough events per hour. Similarly in the second patient the HARQ score decreased from 13 to 9 and objective cough count from 76 to 5 cough events per hour. There was no significant change in spirometric parameters or weight. Conclusion: We have observed early subjective and objective improvement in cough measures on treatment with ivacaftor. We suggest that this improvement could be attributed to improvement of gastro-intestinal function and that cough metrics could be used as early and accurate end points of drug efficacy.
Citation
Faruqi, S., Shiferaw, D., & Morice, A. H. (2016). Effect of ivacaftor on objective and subjective measures of cough in patients with cystic fibrosis. Open Respiratory Medicine Journal, 10, 105-108. https://doi.org/10.2174/1874306401610010105
Journal Article Type | Article |
---|---|
Acceptance Date | Nov 14, 2016 |
Online Publication Date | Dec 30, 2016 |
Publication Date | 2016 |
Deposit Date | May 12, 2022 |
Publicly Available Date | Mar 29, 2024 |
Journal | Open Respiratory Medicine Journal |
Electronic ISSN | 1874-3064 |
Publisher | Bentham Open |
Peer Reviewed | Peer Reviewed |
Volume | 10 |
Pages | 105-108 |
DOI | https://doi.org/10.2174/1874306401610010105 |
Keywords | Cystic fibrosis; Cough; Ivacaftor; Gastro-oesophageal reflux; G551D mutation; Lung function |
Public URL | https://hull-repository.worktribe.com/output/3609886 |
Files
Published article
(484 Kb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by-nc/4.0
Copyright Statement
© Faruqi et al.; Licensee Bentham Open
This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License
(CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
You might also like
Burden of chronic cough in the UK: results from the 2018 National Health and Wellness Survey
(2023)
Journal Article
Downloadable Citations
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search